Evaxion A/S (NASDAQ:EVAX) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Evaxion A/S (NASDAQ:EVAX) released its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.09), FiscalAI reports.

Evaxion A/S Price Performance

Shares of NASDAQ EVAX opened at $3.15 on Thursday. The firm’s 50 day moving average price is $3.14 and its 200 day moving average price is $3.56. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85. Evaxion A/S has a 1 year low of $2.52 and a 1 year high of $12.15. The firm has a market cap of $26.27 million, a P/E ratio of -2.14 and a beta of 0.29.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EVAX. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a research report on Friday, April 24th. Weiss Ratings upgraded Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Trading of Evaxion A/S

An institutional investor recently bought a new position in Evaxion A/S stock. SmartHarvest Portfolios LLC purchased a new position in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,194 shares of the company’s stock, valued at approximately $72,000. SmartHarvest Portfolios LLC owned about 0.18% of Evaxion A/S as of its most recent filing with the Securities & Exchange Commission. 11.04% of the stock is currently owned by institutional investors.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.